



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/995,475	
			Filing Date	November 28, 2001	
			First Named Inventor	Lewis B. Schwartz et al.	
			Art Unit		
			Examiner Name	A. Salimi	
Sheet	1	of	1	Attorney Docket Number	27373/37922

RECEIVED

JAN 31 2003

TECH CENTER 1800/290

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AJ	A1	5,328,688	07/12/1994	Reizman	

Duplicate
AJ

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AJ	C1	Coffin, et al. "Gene Delivery to the Heart <i>In Vivo</i> and to Cardiac Myocytes and Vascular Smooth Muscle Cells <i>In Vitro</i> Using Herpes Virus Vectors," <i>Gene Therapy</i> 3:560-566 (1996).	
AJ	C2	Mesri, et al., "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice," <i>Circulation Research</i> 76:161-167 (1995).	
AJ	C3	Robbins et al., "Viral Vectors for Gene Therapy," <i>Pharmacol. Ther.</i> 80 (1):35-47 (1998).	
AJ	C4	Yeh, et al., "Advances in Adenoviral Vectors: From Genetic Engineering to Their Biology," <i>FASEB Journal</i> 11(8):615-623 (1997).	
AJ	C5	International Search Report, PCT/US01/44279, November 26, 2002.	

Examiner Signature	AJ	Date Considered	2/13/03
-----------------------	----	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27373/37922Serial No.
09/995,475Applicant
Schwartz et al.Filing Date
28 NOV 2001Group
TBA

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

TECH CENTER 1600/1900

APR 17 2002

RECEIVED

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
AS	A1	4,859,587	8/22/89	Roizman	435	68	
	A2	5,288,641	2/22/94	Roizman	435	320.1	
	A3	5,328,688	7/12/94	Roizman	424	205.1	
	A4	5,585,096	12/17/96	Martuza et al.	424	93.2	
	A5	5,599,691	2/4/97	Roizman	435	69.1	
	A6	5,641,651	6/24/79	Roizman	435	69.1	
	A7	5,728,379	3/17/98	Martuza et al.	424	93.2	
	A8	5,795,713	8/18/98	Roizman	435	5	
	A9	5,824,318	10/20/98	Mohr et al.	424	229.1	
	A10	5,837,262	11/17/98	Golubev et al.	424	231.1	
	A11	5,846,707	12/8/98	Roizman	435	5	
	A12	5,851,826	12/22/98	Fraefel et al.	435	325	
	A13	5,879,934	3/9/99	DeLuca	435	320.1	
	A14	6,071,692	6/06/00	Roizman	435	5	
	A15	6,106,826	8/22/00	Brandt et al.	424	93.2	
✓	A16	6,120,773	9/19/00	Roizman	424	205.1	

EXAMINER

AS

DATE CONSIDERED

2/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27373/37922Serial No.
09/995,475Applicant
Schwartz et al.Filing Date
28 NOV 2001Group
TBA

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

As	C1	Advani et al., "Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors," <i>Gene Ther</i> , 5:160-165, 1998.
	C2	Alber et al., "Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse," <i>Circ</i> , 102:779-785, 2000.
	C3	Andreansky et al., "Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors," <i>Can Res</i> , 57:1502-1509, 1997.
	C4	Baumgartner et al., "Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia," <i>Circ</i> , 97:1114-1123, 1998.
	C5	Chambers et al., "Comparison of genetically engineered herpes simplex virus for the treatment of brain tumors in SCID mouse model of human glioma," <i>PNAS</i> , 92:1411-1415, 1995.
	C6	Chandler et al., "RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins," <i>Proc Natl Acad Sci U S A.</i> , 94(8):3596-3601, 1997.
	C7	Chou and Roizman, "Herpes simplex virus 1 gamma-1 34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage," <i>Proc Natl Acad Sci</i> , 91:5247-5251, 1994.
	C8	Chou et al., "Mapping of herpes simplex virus-1 neurovirulence to gamma ₁ 34.5, a gene nonessential for growth in culture," <i>Science</i> , 250:1262-1266, 1990.
↓	C9	Dollery et al., "Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointima hyperplasia in the rat model of vascular balloon injury," <i>Circ</i> , 99:3199-3205, 1999.

EXAMINER

As

DATE CONSIDERED

2/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

APR 17 2002

TECH CENTER 1600 2900



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27373/37922Serial No.
09/995,475Applicant
Schwartz et al.Filing Date
28 NOV 2001Group
TBA**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

RECEIVED

APR 17 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AS	C10	George et al., "Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3," <i>Circ</i> , 101:296-304, 2000.
	C11	Hanna et al., "Adenoviral-mediated expression of antisense RNA to basic fibroblast growth factor reduces tangential stress in arterialized vein grafts," <i>J Vasc Surg</i> , 31:770-780, 2000.
	C12	Huard, Goins, Fink, "Herpes simplex virus type I vector mediated gene transfer to muscle," <i>Gene Ther</i> , 2:385-392, 1995.
	C13	Isner et al., "Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease," <i>Circ</i> , 91:2687-2692, 1995.
	C14	Key et al., "Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression," <i>Proc Natl Acad Sci</i> , 87:7095-7099, 1990.
	C15	Lachmann et al., "The use of herpes simplex virus-based vectors for gene delivery to the nervous system," <i>Molec Med Today</i> , 3:404-411, 1997.
	C16	Martuza et al., "Experimental therapy of human glioma by means of a genetically engineered virus mutant," <i>Science</i> , 252:854-856, 1991.
	C17	Meyerson et al., "The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft," <i>J. Vasc. Surg.</i> , 34:90-97 (2001).
	C18	Mineta, Rabkin, Martuza, "Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant," <i>Cancer Res</i> , 54:3963-3966, 1994.
	C19	Miyatake et al., "Inhibition of rat vascular smooth muscle cell proliferation in vitro and in vivo by recombinant replication-competent herpes simplex virus," <i>Stroke</i> , 30:2431-2438, 1999.
	C20	Moawad et al., "Adenoviral-mediated gene transfer in human and animal vein grafts using clinically relevant exposure times, pressures, and viral concentrations," <i>Ann. Vasc. Surg.</i> , 15:367-373 (2001).
✓	C21	Nabel et al., "Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo," <i>Nature</i> , 362:844-846, 1993.

EXAMINER

DATE CONSIDERED

2/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27373/37922Serial No.
09/995,475Applicant
Schwartz et al.Filing Date
28 NOV 2001Group
TBA

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

TECH CENTER 1600/2900

APR 17 2002

RECEIVED

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

A	C22	Nicolau et al., "Liposomes as carriers for in vivo gene transfer and expression," <i>Methods Enzymol.</i> , 149:157-176, 1987.
	C23	Roizman, B., "The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors," <i>Proc. Natl. Acad. Sci.</i> , 93:11307-11312 (1996).
	C24	Rosengart et al., "Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease," <i>Circ.</i> , 100:468-474, 1999.
	C25	Scheinman, et al., "p53 gene transfer to the injured rat carotid artery decreases neointimal formation," <i>J Vasc Surg</i> , 29:360-369, 1999.
	C26	Schneider et al., "Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors," <i>J Vasc Surg</i> , 29:543-550, 1999.
	C27	Schwartz and Moawad, "Gene therapy for vascular disease," <i>Ann Vasc Surg</i> , 11:189-99, 1997.
	C28	Schwartz et al., "Adenoviral-mediated transfer of a constitutively active form of the retinoblastoma gene product attenuates neointimal thickening in experimental vein grafts," <i>J Vasc Surg</i> , 29:874-883, 1999.
	C29	Svensson et al., "Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors," <i>Circ.</i> , 99:201-205, 1999.
	C30	Symes et al., "Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease," <i>Ann Thor Surg</i> , 68:830-836, 1999.
	C31	Treisman, "Transient Accumulation of c-fos RNA Following Serum Stimulation Requires a Conserved 5' Element and c-fos 3' Sequences," <i>Cell</i> , 42:889, 1985.
✓	C32	Waugh et al., "Thrombomodulin overexpression to limit neointima formation," <i>Circ.</i> , 102:332-337, 2000.

EXAMINER

Ans

DATE CONSIDERED

2/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.